Skip to content

Acupuncture for Blood Pressure Fluctuation During Total Laparoscopic Hysterectomy

Efficacy and safety of acupuncture for blood pressure fluctuation during total laparoscopic hysterectomy : a randomized controlled, parallel-grouped pilot study

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CRIS
Registry ID
KCT0009149
Enrollment
30
Registered
2024-01-31
Start date
2023-10-23
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Procedure/Surgery : acupuncture group: Acupuncture of a disposable, sterilized, stainless steel needle of 0.20 mm * 30 mm size (Dongbang medical, Boryeong, Rep of Korea) will be used. A total 10 acupo

Sponsors

CHA University Ilsan Medical Center
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: between age of 19 and 69, American Society of Anesthesiologists (ASA) class I or II, required surgical removal of uterus by a gynecology specialist, scheduled to have total laparoscopic hysterectomy in advance. agree to participate in clinical trials and providing signed informed consent

Exclusion criteria

Exclusion criteria: expected survival within 3 months, emergency operation which was not scheduled in advance, hypertension or hypotension that can significantly interfere with the study result, diagnosis of arrhythmia, such as atrial fibrillation, frequent ventricular or supraventricular premature beats, diagnosis of heart failure or valvular disease, anemia of hemoglobin < 12 g/dL, incapable of surgery due to hemodynamic or medical reasons other than stated above, incapable of receiving acupuncture treatment on determined location, current use of gonadotropin-releasing hormone receptor agonists, current use of drugs that may interfere with the result, including steroids, immunosuppressants, and psychiatric disorders, significant comorbidities that may interfere with the interpretation of intervention efficacy or results, such as stroke, myocardial infarction, kidney disease, dementia, or epilepsy, pregnant, planning to be pregnant within study period, or breastfeeding, previous participation in any other clinical trial within 1 month of participation, planning to participate another clinical trial within 6 months after enrollment date, or planning to participate another clinical trial on follow-up period, fail to write the informed consent form voluntarily, being deemed to be unsuitable for participation.

Design outcomes

Primary

MeasureTime frame
changes in mean blood pressure

Secondary

MeasureTime frame
blood pressures according to predetermined timepoints;incidence of hypotension;incidence of hypertension;incidence of tachycardia according to predetermined timepoints;incidence of bradycardia according to predetermined timepoints;total use of remifentanil;numeric rating scale for pain;Spielberger's State-Trait Anxiety Inventory (STAI);EuroQoL-5 Dimensions - 5 Levels (EQ-5D-5L)

Countries

Korea, Republic of

Contacts

Public ContactJee Young Lee

CHA University Ilsan Medical Center

happiade@chamc.co.kr+82-31-782-3112

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026